Qvella announced today that it has completed US$20M in Series B Financing to Fund Clinical Trials,
On-going Research, Team Expansion, and Manufacturing Buildup. New strategic investor bioMérieux will explore collaborative opportunities around Qvella’s Field Activated Sample Treatment (FAST) technology in complementary markets.
